For the roughly 38 million Americans living with diabetes, and the hundreds of millions more with prediabetes or metabolic risk, the continuous glucose monitor (CGM) has reshaped how endocrinologists titrate insulin and how patients manage their health. The catch is price. Even after Dexcom's Stelo and Abbott's Lingo received FDA clearance in 2024 for over-the-counter use, a month of sensors remains a significant out-of-pocket expense. That gap is the opening that One Health Biosensing, a New York pre-seed company founded in 2024 by Jeffrey Dachis, says it intends to close [One Health Biosensing, 2024].
The company's public pitch is a next-generation CGM "built and priced to be accessible and affordable on day one," with an ambition to extend the same biosensor chemistry into animal and environmental diagnostics [One Health Biosensing, 2024] [Crunchbase, 2024].
The bet
The wedge One Health Biosensing is describing is hardware economics. The company says its sensor is engineered for ultra-low cost manufacturing and pairs with AI-enabled software for glucose forecasting [Wefunder, 2024]. The intellectual property story is more concrete. Kingscrowd reports more than 50 issued patents associated with the company [Kingscrowd, 2024], and Google Patents lists European Patent EP3977480A1, covering systems for biomonitoring and blood glucose forecasting, originally assigned to Informed Data Systems Inc, doing business as One Drop, the prior Dachis company [Google Patents, 2026].
| Milestone | Detail |
|---|---|
| Founded | February 2024, New York |
| Funding stage | Pre-seed, Wefunder community round, $50,000 minimum target |
| Patent portfolio | More than 50 issued patents |
| Anchor IP | EP3977480A1, biomonitoring and glucose forecasting |
Why the category is moving
CGM is one of the few categories in digital health where unit economics, clinical evidence, and consumer demand are all moving in the same direction. The 2024 OTC clearances from the FDA for Dexcom's Stelo and Abbott's Lingo opened a non-prescription market for adults not on insulin. If a new entrant can credibly cut the per-sensor cost while clearing FDA review, the addressable market extends well beyond the United States into markets where current CGMs are simply unaffordable.
The team and the traction
Jeffrey Dachis is the founder and CEO of One Health Biosensing [Crunchbase, 2024]. He previously founded, chaired, and led One Drop, the diabetes management company whose patent estate appears to underpin the new venture, and he co-founded Razorfish [Crunchbase, 2024] [TechCrunch, 2013]. The Wefunder page references more than $5 billion in cumulative exits across the broader founding team's prior companies [Wefunder, 2024]. Current traction is early: a community round on Wefunder with a $50,000 minimum target [Kingscrowd, 2024].
The honest counterfactual
The bear case is straightforward. Dexcom and Abbott together control the CGM market, both have OTC products on shelves, and both have manufacturing scale and clinical trial infrastructure that a pre-seed company cannot match. Any new CGM in the United States will need either a 510(k) clearance or a de novo pathway. The bull answer is that Dachis is not starting from zero on either chemistry or algorithms: the patent estate, including EP3977480A1, originated inside a company he previously ran [Google Patents, 2026]. Whether that translates into a sensor that performs at parity with incumbents at a fraction of the cost is the empirical question that the next two years of bench data and clinical work will answer.
What to watch
The near-term milestones that will tell readers whether this thesis is real are concrete. First, an institutional seed round with a named life-sciences lead would signal that diligence on the IP and the sensor design held up. Second, any disclosure of an FDA pre-submission meeting, a pilot clinical accuracy study, or a published MARD figure would move the story from pitch to evidence. Third, a manufacturing partner or contract sensor fab announcement would speak to the cost claim.